Alterity Therapeutics (ATHE) EBITDA Margin (2016 - 2024)
Alterity Therapeutics (ATHE) recorded quarterly EBITDA Margin of 0.0% in Q2 2024, up 100.0% quarter-over-quarter from 0.0% in Q2 2023, and little changed on a YoY basis from 0.0% in Q3 2023.
Alterity Therapeutics (ATHE) EBITDA Margin (2016 - 2024) Analysis & Trends
Alterity Therapeutics' EBITDA Margin history runs 6 years deep, the most recent figure standing at 0.0% for Q2 2024.
- In Q2 2024, EBITDA Margin changed 0.0% year-over-year to 0.0%; the TTM figure through Jun 2024 stood at 0.0% (changed 0.0% YoY), while the FY2024 annual figure was 0.0%, changed 0.0% from the prior year.
- EBITDA Margin was 0.0% for Q2 2024 at Alterity Therapeutics, up from 0.0% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 0.0% in Q2 2024 to a low of 0.0% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.59 Bn | 54.83 Bn | 3.31 Bn | 18.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 0.00% |
| Jun 30, 2023 | 0.00% |
| Dec 31, 2019 | -218.14% |
| Dec 31, 2018 | -73.95% |
| Dec 31, 2017 | -308.48% |
| Dec 31, 2016 | -95.29% |